![]() |
|
|
Vol. 302, Issue 2, 433-441, August 2002
Department of Pharmacology, Emory University School of Medicine,
Atlanta, Georgia (M.W., M.J.M., P.J.C.); Department of Neuroscience,
Merck Research Laboratories, West Point, Pennsylvania (M.J.M., P.J.C.);
and Tierphysiologie, University of Tuebingen, Germany (M.W.)
Recent findings have shown that dendritically released dopamine (DA)
plays an important modulatory role in the substantia nigra pars
reticulata (SNr). It is therefore possible that the loss of DA observed
in Parkinson's disease (PD) could hold important consequences for
nigral function. Previously, we have shown that activation of
presynaptically localized group II metabotropic glutamate receptors
(mGluRs) inhibits excitatory transmission at the subthalamic nucleus
(STN)-SNr synapse and that activation of presynaptically localized
group III mGluRs decreases excitatory and inhibitory transmission in
the SNr. To test the hypothesis that nigral DA can modulate mGluR
function in the SNr, we performed whole-cell patch-clamp recordings
from
-aminobutyric acidergic SNr neurons in slices obtained
from rats that were acutely reserpinized. In slices obtained from
reserpinized animals, the effect of group II mGluR activation by the
selective agonist
(+)-2-aminobicyclo[3·1·0]-hexane-2,6-dicarboxylate monohydrate (LY354740) (100 nM), but not group III mGluR activation [L-(+)-2-amino-4-phosphonobutyric acid, L-AP4, 500 µM],
at STN-SNr synapses is significantly decreased. This effect could be
mimicked in control slices by prior bath application of haloperidol (20 µM) and
R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SCH23390) (20 µM) but not sulpiride (50 µM). Furthermore,
application of dopamine (100 µM) and
(±)-6-chloro-7,8-dyhydroxy-3allyl-1-phenyl-2,3,4,5-tetra-hydro-1H-benzazepine (SKF82958) (1 µM) but not quinpirole (10 µM) could rescue the group
II mGluR effect in reserpinized slices. The effect of group III mGluR
activation (L-AP4, 100 µM) on inhibitory synaptic transmission was
also significantly reduced in slices from reserpine-treated animals.
This effect was mimicked by haloperidol (20 µM), SCH23390 (20 µM),
and sulpiride (50 µM) in control slices. Thus, in a Parkinsonian state, the loss of nigral DA may add to the overall pathophysiological changes in basal ganglia output.
This article has been cited by other articles:
![]() |
M. A. Kliem, N. T. Maidment, L. C. Ackerson, S. Chen, Y. Smith, and T. Wichmann Activation of Nigral and Pallidal Dopamine D1-Like Receptors Modulates Basal Ganglia Outflow in Monkeys J Neurophysiol, September 1, 2007; 98(3): 1489 - 1500. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Lopez, N. Turle-Lorenzo, F. Acher, E. De Leonibus, A. Mele, and M. Amalric Targeting Group III Metabotropic Glutamate Receptors Produces Complex Behavioral Effects in Rodent Models of Parkinson's Disease J. Neurosci., June 20, 2007; 27(25): 6701 - 6711. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Vernon, V. Zbarsky, K. P. Datla, D. T. Dexter, and M. J. Croucher Selective Activation of Group III Metabotropic Glutamate Receptors by L-(+)-2-Amino-4-phosphonobutryic Acid Protects the Nigrostriatal System against 6-Hydroxydopamine Toxicity in Vivo J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 397 - 409. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-Z. Shen and S. W. Johnson Subthalamic stimulation evokes complex EPSCs in the rat substantia nigra pars reticulata in vitro J. Physiol., June 15, 2006; 573(3): 697 - 709. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Tyszkiewicz, Z. Gu, X. Wang, X. Cai, and Z. Yan Group II metabotropic glutamate receptors enhance NMDA receptor currents via a protein kinase C-dependent mechanism in pyramidal neurones of rat prefrontal cortex J. Physiol., February 1, 2004; 554(3): 765 - 777. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Valenti, M. J. Marino, M. Wittmann, E. Lis, A. G. DiLella, G. G. Kinney, and P. J. Conn Group III Metabotropic Glutamate Receptor-Mediated Modulation of the Striatopallidal Synapse J. Neurosci., August 6, 2003; 23(18): 7218 - 7226. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Crocker, P. D. Smith, V. Jackson-Lewis, W. R. Lamba, S. P. Hayley, E. Grimm, S. M. Callaghan, R. S. Slack, E. Melloni, S. Przedborski, et al. Inhibition of Calpains Prevents Neuronal and Behavioral Deficits in an MPTP Mouse Model of Parkinson's Disease J. Neurosci., May 15, 2003; 23(10): 4081 - 4091. [Abstract] [Full Text] [PDF] |
||||